Navigation Links
Study Reiterates Eye Risks Linked to Flomax
Date:5/19/2009

Men should be aware of dangers if taking prostate drug, experts say,,

TUESDAY, May 19 (HealthDay News) -- Men taking Flomax to treat an enlarged prostate face more than double the risk for serious complications should they need cataract surgery, a new Canadian study has found.

It's not the first time that Flomax (tamsulosin) has been linked to cataract complications. A study in 2005 found that men taking Flomax or other alpha-blockers before cataract surgery had complications during and immediately after the procedure. The U.S. Food and Drug Administration called for stronger warnings about the drug, and Boehringer Ingelheim Pharmaceuticals, which makes Flomax, sent warning letters to doctors about the potential problems.

In the new study, 7.5 percent of the men who had taken Flomax in the two weeks before cataract surgery had a serious complication, compared with 2.7 percent of those who had not taken the drug, for a 2.3 times greater risk.

The problems were not found to the same extent among men taking other alpha-blockers, said the lead researcher, Dr. Chaim M. Bell, a scientist at the Keenan Research Centre at St. Michael's Hospital in Toronto and assistant professor at the University of Toronto.

"Patients that were prescribed tamsulosin had an over twofold increase in their risk of adverse events after cataract surgery," Bell said. The findings are in the May 20 issue of the Journal of the American Medical Association.

Whether stopping the drug before cataract surgery would reduce the risk of complications is not clear, he said. But before taking Flomax, people should be made aware of the risks, including the risk associated with cataract surgery, he said.

In addition, he said, surgeons need to know if a patient is taking Flomax so that the procedure can be adjusted to take the risks into account. "A better system needs to be in place to better identify patients taking Flomax so that surgeons can best prepare during the operation," he said.

A spokeswoman for Boehringer Ingelheim said the drug maker continues to stand behind its product and believes Flomax is safe when used in the prescribed manner.

"Boehringer Ingelheim is analyzing the data to determine whether it will impact our understanding of the risks and benefits of Flomax capsules in any way," said company spokeswoman Susan Holz.

Information given doctors and patients states "that if patients are considering cataract surgery, they should tell their eye surgeon if they are taking or have taken Flomax," Holz said. "This information is also included in all patient communications regarding Flomax. The Flomax Prescribing Information also states that the patient's eye surgeon should be prepared for possible modifications to the surgical technique for any patient who has taken Flomax."

For the study, Bell's team collected data on 96,128 Canadian men, 66 years and older, who had cataract surgery between 2002 and 2007. Among them, 3,550 had taken Flomax in the two weeks before cataract surgery, and 1,006 had taken the drug more than two weeks before their surgery. In addition, 9,109 men had been taking similar drugs.

In the two weeks after surgery, 284 of the men had a serious complication. Of these, 175 underwent another operation because of a lost lens or lens fragment, 35 had retinal detachment and 26 had both complications. An additional 100 had suspected inflammation within or around the eye.

Flomax is often prescribed to treat an enlarged prostate, a condition known as benign prostatic hyperplasia, or BPH, which affects almost three of four men 70 and older. Symptoms include difficulty urinating. Flomax accounted for $1 billion in sales in 2007, according to the researchers.

Dr. David F. Chang, a clinical professor of ophthalmology at the University of California, San Francisco, said that the study strengthens the existing evidence about risks associated with taking Flomax before cataract surgery.

Most doctors who perform cataract surgery, Chang said, would not start taking the drug themselves if they knew they were likely to need cataract surgery. "If we ophthalmologist were patients, we would want to hear about some of the options," he said. "If I needed cataract surgery, I might want to put off taking any alpha-blocker or possibly take another drug."

Chang was a researcher on the original study that linked Flomax with cataract surgery complications, and "this study supports the observations we laid out," he said.

But, he said, because the risks of complications are relatively small, men who are already taking Flomax should not stop taking the drug and should not be afraid to undergo cataract surgery. "The risks are acceptable," he said. "On the other hand, it would be a shame to have a patient start on an elective medicine like Flomax within a few months of when they need cataract surgery."

More information

The U.S. National Eye Institute has more on cataracts.



SOURCES: Chaim M. Bell, M.D., Ph.D., scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, and assistant professor, University of Toronto; David F. Chang, M.D., clinical professor, ophthalmology, School of Medicine, University of California, San Francisco; Susan Holz, spokeswoman, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn.; May 20, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Shows NeuroStar TMS Therapy(R) Improved Key Elements of Cognition in Patients with Major Depressive Disorder
2. BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels
3. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
4. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
5. MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR
6. Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System
7. Workplace E-Mail Intervention Program Helps People Sit Less and Eat Better, Kaiser Permanente Study Finds
8. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
9. Study Cites Gains in Gall Bladder Cancer Treatment
10. Mock CPR drills in kids show many residents fail in key skills, Hopkins study reveals
11. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Reiterates Eye Risks Linked to Flomax
(Date:5/25/2016)... , ... May 25, 2016 , ... According to an ... type of hernia mesh that would effectively fight against common bacteria and protect against ... the healing process from hernia repair surgery even safer and could further ...
(Date:5/25/2016)... ... 25, 2016 , ... The Horizon Foundation for New Jersey ... to improve oral health-related awareness, education, prevention and treatment for young people. The ... promote best practices in 10 New Jersey counties where dental health needs among ...
(Date:5/25/2016)... ... , ... The Bank of America Charitable Foundation has awarded a grant to ... pathway to employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, ... CEO of Medisend, parent organization and home of the General Myers Veterans Program. ...
(Date:5/25/2016)... ... 25, 2016 , ... Today American University of Antigua (AUA) ... announced the AUA-FIU Global MD Program. Students in the Global MD Program ... a Certificate of Completion from the FIU Herbert Wertheim College of Medicine Clinical ...
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who ... O’Fallon, MO 63366. He serves patients of all ages with a full menu of ... success is reflected in the superior patient reviews that he has consistently earned during ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
Breaking Medicine Technology: